Graft vs Host Disease Clinical Trials

21 recruitingLast updated: June 18, 2026

There are 21 actively recruiting graft vs host disease clinical trials across 7 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 4. Top locations include Wuhan, Hubei, China, Bethesda, Maryland, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Graft vs Host Disease Trials at a Glance

21 actively recruiting trials for graft vs host disease are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Wuhan, Bethesda, and Boston. Lead sponsors running graft vs host disease studies include Dana-Farber Cancer Institute, National Cancer Institute (NCI), and WeiShi.

Browse graft vs host disease trials by phase

Treatments under study

About Graft vs Host Disease Clinical Trials

Looking for clinical trials for Graft vs Host Disease? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Graft vs Host Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Graft vs Host Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 4

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Graft vs Host DiseaseChronic Graft vs. Host DiseaseCorticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals50 enrolled22 locationsNCT06824103
Recruiting

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Graft vs Host DiseaseGraft-versus-leukemiaGraft Rejection
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00106925
Recruiting
Phase 4

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationCytomegalovirus Infections+1 more
WeiShi120 enrolled12 locationsNCT07569653
Recruiting
Phase 2

Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD

Graft vs Host Disease
Chang Gung Memorial Hospital35 enrolled1 locationNCT07364617
Recruiting
Phase 1Phase 2

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Graft vs Host Disease
National Cancer Institute (NCI)50 enrolled2 locationsNCT05531786
Recruiting
Phase 2

A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT

Chronic Graft Versus Host DiseaseGraft vs Host Disease
WeiShi30 enrolled1 locationNCT07606703
Recruiting
Phase 2

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

Graft vs Host Disease
Boston Children's Hospital160 enrolled15 locationsNCT04380740
Recruiting

Pediatric cGVHD Symptom Scale

Graft vs Host Disease
National Cancer Institute (NCI)420 enrolled17 locationsNCT04044365
Recruiting
Phase 1

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Graft vs Host DiseaseGraft-Versus-Host Disease
Washington University School of Medicine41 enrolled1 locationNCT06008808
Recruiting
Phase 2

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Hematologic MalignancyGraft vs Host DiseaseGraft-Versus-Host Disease
Memorial Sloan Kettering Cancer Center46 enrolled8 locationsNCT07006506
Recruiting
Not Applicable

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

Graft vs Host DiseaseGraft-Versus-Host Disease
Christopher Dvorak90 enrolled1 locationNCT04337515
Recruiting
Not Applicable

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

Acute Graft Versus Host DiseaseChronic Graft Versus Host DiseaseGraft vs Host Disease
Dana-Farber Cancer Institute36 enrolled2 locationsNCT05236062
Recruiting

Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

Graft vs Host DiseaseVulvovaginal Signs and Symptoms
Case Comprehensive Cancer Center40 enrolled1 locationNCT06649201
Recruiting

Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain.

Cognitive DysfunctionFatigueGraft vs Host Disease
Karolinska University Hospital30 enrolled1 locationNCT07365696
Recruiting
Phase 1

IS-free Treg HaploHCT

Myelodysplastic SyndromesStem Cell Transplant ComplicationsGraft vs Host Disease+2 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT04678401
Recruiting
Not Applicable

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Graft vs Host Disease
First Affiliated Hospital of Zhejiang University122 enrolled1 locationNCT07184853
Recruiting
Phase 2

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Vitamin A deficiencyGraft vs Host DiseaseVitamin D Deficiency
Children's Hospital Medical Center, Cincinnati190 enrolled3 locationsNCT06450925
Recruiting
Phase 1Phase 2

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Graft vs Host Disease
Northwell Health10 enrolled1 locationNCT06681922
Recruiting
Not Applicable

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

Graft vs Host DiseaseGraft RejectionCutaneous T Cell Lymphoma
Centre Hospitalier Universitaire de Besancon20 enrolled1 locationNCT05333367
Recruiting
Phase 1

Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD

Graft vs Host Disease
Fujian Medical University17 enrolled1 locationNCT06568328